Sage Therapeutics Inc (SAGE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jeff Jonas
Employees:
637
215 FIRST STREET, CAMBRIDGE, MA 02142
617-299-8380

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 2.437 Billion Shares Outstanding58.811 Million Avg 30-day Volume 442.423 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 98.39 / 39.77 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from SAGE instead.

View recent insider trading info

Funds Holding SAGE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SAGE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

JONAS JEFFREY M CHIEF INNOVATION OFFICER

80,863 2021-10-19 4

IGUCHI KIMI CFO & TREASURER

47,600 2021-10-19 5

COOK ANNE MARIE SVP, GC & SECRETARY

7,894 2021-10-19 3

KANES STEPHEN CHIEF MEDICAL OFFICER

13,471 2021-10-19 3

ROBICHAUD ALBERT CHIEF SCIENTIFIC OFFICER

142,619 2021-10-19 3

BENECCHI CHRISTOPHER CHIEF COMMERCIAL OFFICER

45,000 2021-10-01 2

GREENE BARRY E PRESIDENT AND CEO

32,440 2021-08-05 3

STARR KEVIN P

320,659 2021-06-16 2

FRATES JAMES M

2,845 2021-06-16 2

COLA MICHAEL F

10,000 2021-06-10 1

PAUL STEVEN M

10,000 2021-06-10 1

GERMANO GENO J

10,000 2021-06-10 1

GOLUMBESKI GEORGE

10,000 2021-06-10 2

BARRETT ELIZABETH

10,000 2021-06-10 2

CLOONAN MICHAEL CHIEF BUSINESS OFFICER

0 2021-02-10 1

BIOGEN INC.

BIOGEN MA INC.

  • 10% Owner
6,241,473 2020-12-31 1

NAYAK ASHA

0 2019-06-05 0

ANDERSON THOMAS SEE REMARKS

0 2017-02-06 0

THIRD ROCK VENTURES II, L.P.

THIRD ROCK VENTURES GP II, L.P.

TRV GP II, LLC

LEVIN MARK J

TEPPER ROBERT I

  • 10% Owner
3,170,750 2016-08-19 0

PIEN HOWARD H

0 2016-06-22 0

NELSEN ROBERT

  • Director
1,232,649 2015-11-09 0

ARCH VENTURE FUND VII LP

ARCH VENTURE PARTNERS VII, L.P.

ARCH VENTURE PARTNERS VII, LLC

CRANDELL KEITH

BYBEE CLINTON

  • 10% Owner
No longer subject to file 2015-06-18 0

STEBEN KENNETH E PRESIDENT

  • Officer
  • Director
  • 10% Owner
0 2010-12-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

JONAS JEFFREY M CHIEF INNOVATION OFFICER

2021-10-21 16:03:09 -0400 2021-10-19 F 4,374 $40.29 d 80,863 direct 0.0241 0.0241 2 0.0 1

COOK ANNE MARIE SVP, GC & SECRETARY

2021-10-21 16:03:22 -0400 2021-10-19 A 3,800 a 9,010 direct 0.0241 0.0241 2 0.0 1

IGUCHI KIMI CFO & TREASURER

2021-10-21 16:04:02 -0400 2021-10-19 F 1,024 $40.29 d 47,600 direct 0.0241 0.0241 2 0.0 1

KANES STEPHEN CHIEF MEDICAL OFFICER

2021-10-21 16:02:51 -0400 2021-10-19 F 1,120 $40.29 d 13,471 direct 0.0241 0.0241 2 0.0 1

JONAS JEFFREY M CHIEF INNOVATION OFFICER

2021-10-21 16:03:09 -0400 2021-10-19 A 10,000 a 85,237 direct 0.0241 0.0241 2 0.0 1

ROBICHAUD ALBERT CHIEF SCIENTIFIC OFFICER

2021-10-21 16:03:51 -0400 2021-10-19 F 1,116 $40.29 d 142,619 direct 0.0241 0.0241 2 0.0 1

IGUCHI KIMI CFO & TREASURER

2021-10-21 16:04:02 -0400 2021-10-19 A 3,800 a 48,624 direct 0.0241 0.0241 2 0.0 1

KANES STEPHEN CHIEF MEDICAL OFFICER

2021-10-21 16:02:51 -0400 2021-10-19 A 3,800 a 14,591 direct 0.0241 0.0241 2 0.0 1

COOK ANNE MARIE SVP, GC & SECRETARY

2021-10-21 16:03:22 -0400 2021-10-19 F 1,116 $40.29 d 7,894 direct 0.0241 0.0241 2 0.0 1

ROBICHAUD ALBERT CHIEF SCIENTIFIC OFFICER

2021-10-21 16:03:51 -0400 2021-10-19 A 3,800 a 143,735 direct 0.0241 0.0241 2 0.0 1

BENECCHI CHRISTOPHER CHIEF COMMERCIAL OFFICER

2021-10-04 16:10:30 -0400 2021-10-01 A 45,000 a 45,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SAGE THERAPEUTICS INC SAGE 2021-10-26 18:45:03 UTC -0.198 0.268 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 18:15:03 UTC -0.198 0.268 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 17:45:03 UTC -0.198 0.268 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 17:15:03 UTC -0.198 0.268 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 16:45:04 UTC -0.2004 0.2704 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 16:15:03 UTC -0.2004 0.2704 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 15:45:03 UTC -0.2004 0.2704 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 15:15:03 UTC -0.2004 0.2704 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 14:45:03 UTC -0.18 0.25 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 14:15:05 UTC -0.18 0.25 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 13:45:03 UTC -0.18 0.25 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 13:15:03 UTC -0.18 0.25 950000
SAGE THERAPEUTICS INC SAGE 2021-10-26 12:45:03 UTC -0.18 0.25 900000
SAGE THERAPEUTICS INC SAGE 2021-10-25 22:15:03 UTC -0.18 0.25 850000
SAGE THERAPEUTICS INC SAGE 2021-10-25 21:45:03 UTC -0.18 0.25 850000
SAGE THERAPEUTICS INC SAGE 2021-10-25 21:15:03 UTC -0.18 0.25 850000
SAGE THERAPEUTICS INC SAGE 2021-10-25 20:45:03 UTC -0.18 0.25 850000
SAGE THERAPEUTICS INC SAGE 2021-10-25 20:15:03 UTC -0.18 0.25 850000
SAGE THERAPEUTICS INC SAGE 2021-10-25 19:45:04 UTC -0.18 0.25 850000
SAGE THERAPEUTICS INC SAGE 2021-10-25 19:15:03 UTC -0.18 0.25 850000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund SAGE -806.0 shares, $-58185.14 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund SAGE -621.0 shares, $-44829.99 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund SAGE -2065.0 shares, $-289698.85 2019-09-30 N-PORT
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund SAGE -6074.0 shares, $-852121.46 2019-09-30 N-PORT
Trust for Professional Managers- Convergence Market Neutral Fund SAGE -1277.0 shares, $-66965.88 2020-08-31 N-PORT
FundVantage Trust- Gotham Enhanced Index Plus Fund SAGE -135.0 shares, $-3877.2 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund SAGE -118.0 shares, $-3388.96 2020-03-31 N-PORT
AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund SAGE -695.0 shares, $-97501.55 2019-09-30 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund SAGE -184.0 shares, $-5284.48 2020-03-31 N-PORT
JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund SAGE -4859.0 shares, $-363696.15 2021-03-31 N-PORT
RBB Fund, Inc.- Boston Partners Long/Short Research Fund SAGE -16431.0 shares, $-1143597.6 2021-05-31 N-PORT
TIFF INVESTMENT PROGRAM- TIFF Multi-Asset Fund SAGE -1643.0 shares, $-93338.83 2021-06-30 N-PORT
AdvisorShares Trust- AdvisorShares Dorsey Wright Short ETF SAGE -3600.0 shares, $-204516.0 2021-06-30 N-PORT
AQR Funds- AQR Alternative Risk Premia Fund SAGE -4639.0 shares, $-263541.59 2021-06-30 N-PORT
AQR Funds- AQR Multi-Asset Fund SAGE -102.0 shares, $-5794.62 2021-06-30 N-PORT
VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND SAGE -1859.0 shares, $-81294.07 2021-07-31 N-PORT

Elevate your investments